ES2190802T3 - Procedimientos y composiciones para la identificacion sensible, rapida y funcional de polinucleotidos genomicos, y su utilizacion para ensayos celulares en la puesta a punto de farmacos. - Google Patents

Procedimientos y composiciones para la identificacion sensible, rapida y funcional de polinucleotidos genomicos, y su utilizacion para ensayos celulares en la puesta a punto de farmacos.

Info

Publication number
ES2190802T3
ES2190802T3 ES97943625T ES97943625T ES2190802T3 ES 2190802 T3 ES2190802 T3 ES 2190802T3 ES 97943625 T ES97943625 T ES 97943625T ES 97943625 T ES97943625 T ES 97943625T ES 2190802 T3 ES2190802 T3 ES 2190802T3
Authority
ES
Spain
Prior art keywords
cell
pharmacos
procedures
sensitive
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97943625T
Other languages
English (en)
Inventor
Michael A Whitney
Paul A Negulescu
Frank Craig
Lora Mere
Gorden J Foulkes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals San Diego LLC
Original Assignee
Vertex Pharmaceuticals San Diego LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals San Diego LLC filed Critical Vertex Pharmaceuticals San Diego LLC
Application granted granted Critical
Publication of ES2190802T3 publication Critical patent/ES2190802T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/986—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides (3.5.2), e.g. beta-lactamase (penicillinase, 3.5.2.6), creatinine amidohydrolase (creatininase, EC 3.5.2.10), N-methylhydantoinase (3.5.2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A PROCEDIMIENTOS Y COMPOSICIONES PARA LA IDENTIFICACION DE PROTEINAS O SUSTANCIAS QUIMICAS QUE MODULAN DIRECTA E INDIRECTAMENTE UN POLINUCLEOTIDO GENOMICO, ASI COMO A PROCEDIMIENTOS DE IDENTIFICACION DE POLINUCLEOTIDOS GENOMICOS ACTIVOS. EN GENERAL, EL PROCEDIMIENTO CONSISTE EN INSERTAR UNA CONSTRUCCION DE EXPRESION DE BL (BETA LACTAMASA) EN UN GENOMA EUCARIOTICO, NORMALMENTE SIN LEVADURA, QUE CONTIENE, POR LO MENOS, UNA CELULA VIVA, QUE ENTRA EN CONTACTO CON LA CELULA QUE TIENE UNA CONCENTRACION PREDETERMINADA DE UN MODULADOR Y DETECTA LA ACTIVIDAD DE LA BL EN LA CELULA.
ES97943625T 1996-09-26 1997-09-26 Procedimientos y composiciones para la identificacion sensible, rapida y funcional de polinucleotidos genomicos, y su utilizacion para ensayos celulares en la puesta a punto de farmacos. Expired - Lifetime ES2190802T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/719,697 US5928888A (en) 1996-09-26 1996-09-26 Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities

Publications (1)

Publication Number Publication Date
ES2190802T3 true ES2190802T3 (es) 2003-08-16

Family

ID=24891025

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02010958T Expired - Lifetime ES2315327T4 (es) 1996-09-26 1997-09-26 Procedimientos y composiciones para determinar los perfiles de respuesta celular.
ES97943625T Expired - Lifetime ES2190802T3 (es) 1996-09-26 1997-09-26 Procedimientos y composiciones para la identificacion sensible, rapida y funcional de polinucleotidos genomicos, y su utilizacion para ensayos celulares en la puesta a punto de farmacos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES02010958T Expired - Lifetime ES2315327T4 (es) 1996-09-26 1997-09-26 Procedimientos y composiciones para determinar los perfiles de respuesta celular.

Country Status (10)

Country Link
US (1) US5928888A (es)
EP (2) EP1262478B9 (es)
AT (2) ATE229508T1 (es)
AU (1) AU4505797A (es)
CA (2) CA2409901A1 (es)
DE (2) DE69739110D1 (es)
DK (2) DK0952976T3 (es)
ES (2) ES2315327T4 (es)
PT (1) PT1262478E (es)
WO (1) WO1998013353A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955275A (en) 1997-02-14 1999-09-21 Arcaris, Inc. Methods for identifying nucleic acid sequences encoding agents that affect cellular phenotypes
US6207371B1 (en) * 1996-10-04 2001-03-27 Lexicon Genetics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US6060240A (en) * 1996-12-13 2000-05-09 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
US6623922B1 (en) 1997-02-14 2003-09-23 Deltagen Proteomics Methods for identifying, characterizing, and evolving cell-type specific CIS regulatory elements
US7853411B2 (en) 1997-02-27 2010-12-14 Cellomics, Inc. System for cell-based screening
US6759206B1 (en) 1997-02-27 2004-07-06 Cellomics, Inc. System for cell-based screening
ATE466948T1 (de) * 1997-03-11 2010-05-15 Univ Minnesota Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle
US6214563B1 (en) * 1997-08-01 2001-04-10 Aurora Biosciences Corporation Photon reducing agents for reducing undesired light emission in assays
US6200762B1 (en) * 1997-08-01 2001-03-13 Aurora Biosciences Corporation Photon reducing agents and compositions for fluorescence assays
US6221612B1 (en) * 1997-08-01 2001-04-24 Aurora Biosciences Corporation Photon reducing agents for use in fluorescence assays
US6828099B2 (en) * 1998-02-02 2004-12-07 Odyssey Thera Inc. Protein fragment complementation assay (PCA) for the detection of protein-protein, protein-small molecule and protein nucleic acid interactions based on the E. coli TEM-1 β-Lactamase
US6284461B1 (en) * 1998-04-28 2001-09-04 Aurora Biosciences Corporation Use of inhibitors in reporter assays
US6280934B1 (en) * 1998-05-13 2001-08-28 Millennium Pharmaceuticals, Inc. Assay for agents which alter G-protein coupled receptor activity
US6031094A (en) * 1998-07-23 2000-02-29 The Regents Of The University Of California Beta-lactam substrates and uses thereof
ATE485834T1 (de) 1998-09-08 2010-11-15 Ford Henry Health System Verfahren zum nachweis von bindegewebswachstumsfaktor zur diagnose von nierkrankheiten
US6063578A (en) * 1998-10-22 2000-05-16 Signal Pharmaceuticals, Inc. Dual reporter system and methods of use therefor
US7160682B2 (en) * 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
US6835540B2 (en) * 2001-03-16 2004-12-28 Mendel Biotechnology, Inc. Biosynthetic pathway transcription factors
CA2369969A1 (en) * 1999-04-15 2000-10-26 Curagen Corporation Method of identifying toxic agents using differential gene expression
CA2377768A1 (en) * 1999-07-02 2001-01-11 Curagen Corporation Method of identifying toxic agents using differential gene expression
WO2001053481A1 (en) * 2000-01-20 2001-07-26 Cell Therapeutics, Inc. Methods and compositions for identification of genomic polynucleotides which are transcriptionally regulated
WO2001053355A1 (en) 2000-01-24 2001-07-26 The Trustees Of Columbia University In The City Of New York An in vivo screen using chemical inducers of dimerization
US20060134629A1 (en) * 2000-03-20 2006-06-22 Link Charles J Methods and compositions for elucidating protein expression profiles in cells
US6897020B2 (en) * 2000-03-20 2005-05-24 Newlink Genetics Inc. Methods and compositions for elucidating relative protein expression levels in cells
US7029842B2 (en) 2000-04-07 2006-04-18 Novozymes A/S Signal sequence trapping
EP1276857B1 (en) * 2000-04-07 2008-06-11 Novozymes A/S Signal sequence trapping
WO2002020749A2 (en) * 2000-09-07 2002-03-14 Owman Christer S O Chimeric reporter system for cell surface receptor-ligand binding
US20020127557A1 (en) * 2001-03-09 2002-09-12 Ruoying Tan Method for identification of cDNAs encoding signal peptides
AU2002255771B2 (en) * 2001-03-16 2007-10-18 Qtl Biosystems, Llc Fluorescent polymer superquenching-based bioassays
ATE328109T1 (de) * 2001-05-04 2006-06-15 Health Research Inc Test mit hohem durchsatz zur identifizierung von modifikatoren der genexpression
MXPA04001725A (es) * 2001-08-24 2005-04-11 Advanced Cell Tech Inc ANáLISIS DE SELECCION PARA IDENTIFICAR AGENTES INDUCTORES DE DIFERENCIACION Y PRODUCCION DE CELULAS DIFERENCIADAS PARA TERAPIA CELULAR.
WO2003027260A2 (en) * 2001-09-27 2003-04-03 Functional Genetics, Inc. Methods and compositions for generating homozygous mutations
US20030170611A1 (en) * 2002-03-09 2003-09-11 Cardone Michael H. Cell-based screening methods
US20030170850A1 (en) * 2002-03-09 2003-09-11 Cardone Michael H. Cell-based screening methods
US6730492B2 (en) * 2002-03-09 2004-05-04 Merrimack Pharmaceuticals, Inc. Cell-based screening methods
US20050181464A1 (en) * 2002-04-04 2005-08-18 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from bacteria
WO2003089618A2 (en) * 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Transposon system and methods of use
US7083918B2 (en) 2002-04-24 2006-08-01 The Trustees Of Columbia University In The City Of New York Bacterial small-molecule three-hybrid system
US20040219563A1 (en) * 2002-10-16 2004-11-04 Michael West Method using gene trapped stem cells for making pathways of stem cell differentiation and making and isolating differentiated cells
CA2513730A1 (en) * 2003-01-16 2004-08-05 Health Research, Inc. Method for comprehensive identification of cell lineage specific genes
US9068234B2 (en) * 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US8460864B2 (en) 2003-01-21 2013-06-11 Ptc Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
US8426194B2 (en) 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
WO2004085608A2 (en) * 2003-03-27 2004-10-07 Newlink Genetics Corporation Methods for high throughput elucidation of transcriptional profiles and genome annotation
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
SE0302840D0 (sv) * 2003-10-29 2003-10-29 Affibody Ab Detection method
WO2005049868A1 (en) * 2003-11-17 2005-06-02 Pct Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating her2 expression
GB0410105D0 (en) * 2004-05-06 2004-06-09 Amersham Biosciences Uk Ltd Method for characterising compounds
WO2005113791A2 (en) * 2004-05-07 2005-12-01 Johnson & Johnson Product Research And Development Methods of identifying modulators of bacterial type iii protein secretion system
US20060026699A1 (en) * 2004-06-04 2006-02-02 Largaespada David A Methods and compositions for identification of genomic sequences
US20070044343A1 (en) * 2005-08-30 2007-03-01 Harris Rodger M Disposable footwear cover
US8283115B1 (en) 2007-06-20 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
AU2013359166B2 (en) * 2012-12-12 2019-09-19 Promega Corporation Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer
WO2022082025A1 (en) * 2020-10-16 2022-04-21 Biomems Analytics Llc Cellular response analysis method
MX2023007788A (es) 2021-01-24 2023-11-17 Michael David Forrest Inhibidores de la atp sintasa, usos cosmeticos y terapeuticos.

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4935363A (en) * 1987-03-30 1990-06-19 Board Of Regents, The University Of Texas System Sterol regulatory elements
US5378603A (en) * 1987-03-30 1995-01-03 Board Of Regents, The University Of Texas System Method and composition for identifying substances which activate transcription of the LDL receptor gene
EP0291893A1 (en) * 1987-05-19 1988-11-23 The Du Pont Merck Pharmaceutical Company Stable human cell lines expressing an indicator gene product under virus-specific genetic controls
US5266464A (en) * 1988-02-10 1993-11-30 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US4980281A (en) * 1988-02-10 1990-12-25 Housey Gerard M Method of screening for protein inhibitors and activators
US5264354A (en) * 1988-09-30 1993-11-23 Eli Lilly And Company Method for isolating transposable elements from streptomyces
JPH04503306A (ja) * 1989-02-01 1992-06-18 ザ・ジェネラル・ホスピタル・コーポレーション 単純ヘルペスウイルス１型発現ベクター
US5665543A (en) * 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
US5580722A (en) * 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
AU660405B2 (en) * 1989-07-18 1995-06-29 Osi Pharmaceuticals, Inc. Method of transcriptionally modulating gene expression and of discovering chemicals capable of functioning as gene expression modulators
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5364783A (en) * 1990-05-14 1994-11-15 Massachusetts Institute Of Technology Retrovirus promoter-trap vectors
US5614396A (en) * 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5401629A (en) * 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
FI931268L (fi) * 1990-09-24 1993-04-21 Gen Hospital Corp Saollningsfoerfaranden
CA2072581A1 (en) * 1990-10-25 1992-04-26 Clague Hodgson Method of gene transfer using retrotransposons
US5639596A (en) * 1991-08-16 1997-06-17 Gsf-Forschungszentrum Fur Umweltund Gesundheit DNA construct and in vitro test for detecting tumor promoters by means of said DNA construct
US5326691A (en) * 1991-11-21 1994-07-05 John Hozier Micro-libraries and methods of making and manipulating them methods for generating and analyzing micro-libraries
DE4138621A1 (de) * 1991-11-25 1993-06-17 Boehringer Ingelheim Int Verfahren zum screenen von substanzen mit modulierender wirkung auf einen rezeptorabhaengigen zellulaeren signaluebertragungsweg
US5338843A (en) * 1992-01-30 1994-08-16 Becton, Dickinson And Company Fluorogenic and chromogenic β-lactamase substrates
WO1993025712A1 (en) * 1992-06-15 1993-12-23 The Regents Of The University Of California Screening assay for the identification of immunosuppressive drugs
WO1994001137A1 (en) * 1992-07-06 1994-01-20 Hybritech Incorporated Method for delivery of cytotoxic agents and components thereof
US5652128A (en) * 1993-01-05 1997-07-29 Jarvik; Jonathan Wallace Method for producing tagged genes, transcripts, and proteins
HK1004920A1 (en) * 1993-01-21 1998-12-11 President And Fellows Of Harvard College Methods and diagnostic kits utilizing mammalian stress promoters to determine toxicity of a compound
JPH09501302A (ja) * 1993-04-07 1997-02-10 キャンサー リサーチ キャンペーン テクノロジー リミティド 治療活性についての物質のスクリーニングのための方法及びそれにおいて利用するための方法
JP4375759B2 (ja) * 1993-04-21 2009-12-02 ザ・ユニバーシティ・コート・オブ・ザ・ユニバーシティ・オブ・エディンバラ 標的とされた発現特性に従う異種遺伝子の発現
US5704555A (en) * 1993-08-02 1998-01-06 Illinois Institute Of Technology Single-screw extruder for solid state shear extrusion pulverization and method
GB9317193D0 (en) * 1993-08-18 1993-10-06 Zeneca Ltd Method
US5604090A (en) * 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
AU1916595A (en) * 1994-08-12 1996-03-07 Enzymed, Inc. Biocatalytic methods for synthesizing and identifying biologically active compounds
GB9423367D0 (en) * 1994-11-18 1995-01-11 Wellcome Found Enzyme prodrug therapy
US5789653A (en) * 1995-01-10 1998-08-04 University Of Edinburgh Secretory gene trap
US5741657A (en) * 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
US5569588A (en) * 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5777888A (en) * 1995-08-09 1998-07-07 Regents Of The University Of California Systems for generating and analyzing stimulus-response output signal matrices
GB9523703D0 (en) * 1995-11-20 1996-01-24 Wellcome Found Enzyme prodrug thearapy

Also Published As

Publication number Publication date
ATE229508T1 (de) 2002-12-15
US5928888A (en) 1999-07-27
EP0952976A1 (en) 1999-11-03
EP0952976B1 (en) 2002-12-11
ATE414165T1 (de) 2008-11-15
DE69739110D1 (de) 2008-12-24
EP1262478A3 (en) 2003-03-26
EP0952976A4 (es) 1999-12-01
EP1262478B1 (en) 2008-11-12
DK1262478T3 (da) 2009-02-09
CA2266978C (en) 2005-06-07
AU4505797A (en) 1998-04-17
CA2409901A1 (en) 1998-04-02
EP1262478A2 (en) 2002-12-04
EP1262478B9 (en) 2009-04-15
ES2315327T4 (es) 2009-10-21
PT1262478E (pt) 2009-01-20
DE69717856D1 (de) 2003-01-23
DK0952976T3 (da) 2003-04-07
ES2315327T3 (es) 2009-04-01
CA2266978A1 (en) 1998-04-02
WO1998013353A1 (en) 1998-04-02
DE69717856T2 (de) 2004-02-19

Similar Documents

Publication Publication Date Title
ES2190802T3 (es) Procedimientos y composiciones para la identificacion sensible, rapida y funcional de polinucleotidos genomicos, y su utilizacion para ensayos celulares en la puesta a punto de farmacos.
ATE386815T1 (de) Methoden und syteme zur überwachung intrazellulärer bindereaktionen
WO2005010494A3 (en) Multiplexed analyte detection
DE69213826D1 (de) Teststreifen mit Merocyanin und Nitro- oder Nitroso-substituierten polyhalogenierten Phenolsulfonphthaleinen als Protein-Indikatoren
TWI256975B (en) Compositions containing a urea derivative dye for detecting an analyte and methods for using the same
FI950487A7 (fi) Menetelmä, reagenssi ja testipakkaus nukleiinihapposekvenssien totamis eksi ja monistamiseksi
ATE461450T1 (de) Verwendung von kontrollflächen zur detektion von störproben in einem nachweisverfahren
EP1170380A3 (en) Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
PT1137943E (pt) Metodo e reagentes para a deteccao de cancro
WO2004011144A3 (en) Transparent polymer support for electrophoresis and electrochromatography and related methods
DE69823373D1 (de) Methode zum nachweis von organismen in einer testprobe
DK662789A (da) Fremgangsmaade til paavisning af den eventuelle tilstedevaerelse af en specifik nucleinsyresekvens i en proeve samt fremgangsmaade og proevesaet til forstaerkning af maalsekvensen
DK382880A (da) Chromogene forbindelser samt deres anvendelse som enzymsubstrater
FI946127A7 (fi) Menetelmä alukkeen pidentämiseksi yhdellä nukleotidilla spesifisten al leelien detektoimiseksi, ja testipakkaus näiden menetelmien suorittami seksi
ATE229571T1 (de) Nachweis und identifizierung von nicht-polio enteroviren
DE59911255D1 (de) ELISPOT-Verfahren zur Quantifizierung der Aktivität von menschlichen und tierischen Zellen, zur insbesondere Blutzellen
WO2001042503A3 (en) Apparatus and methods for drug screening based on nucleic acid analysis
DK1560929T3 (da) Polynucleotider til amplifikation og detektion af chlamydia trachomatis og neisseria gonore
DE59814032D1 (de) Nucleinsäuremolekül, kit und verwendung
DE59907982D1 (de) Verfahren zum Nachweis einer bei Apoptose aktivierten Protease
DE69632826D1 (de) Nukleinsaeure erkennung von hepatitis gb virus
DE60121547D1 (de) Electrochemisches verfahren zum nachweis von nukleinsäuren
DE59910326D1 (de) Verwendung derivatisierter Reagenzien in Chemilumineszenz- und Elektrochemilumineszenz-Nachweisverfahren
EP1187934A4 (en) Cell-based assay for screening cox-2 inhibitors
WO2000034777A3 (de) Verfahren zur bestimmung von biologischen langzeitwirkungen von stoffen